Articles

On March 30, 2011, the Centers for Medicare & Medicaid Services (CMS) announced its highly anticipated proposed national coverage decision concerning the prostate cancer immunotherapy sipuleucel-T (Provenge; Dendreon).

The Potential for Personalized Medicine to Improve the Value of Targeted Therapy

By Yu-Ning Wong, MD, MSCE

Economics & Value, Value-Based Care, VBCC Perspectives

April 2011, Vol 2, No 2

Potential New Options for Neuroendocrine Prostate Cancer

Genitourinary Cancers Symposium, Prostate Cancer

April 2011, Vol 2, No 2

Large Study Rules PSA Test Unnecessary >10 Years after Radical Prostatectomy

By Debra Wood, RN

Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

CyberKnife Cost-Effective in the Long-Term

By Debra Wood, RN

Genitourinary Cancers Symposium, Prostate Cancer

April 2011, Vol 2, No 2

Mutational Analysis Leads Search for New Treatments for Bladder Cancer

By Debra Wood, RN

Bladder Cancer, Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Abiraterone Acetate Prolongs Survival in Metastatic Prostate Cancer

By Debra Wood, RN

Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Accelerating Growth in REMS Programs a Challenge for Oncologists

By Daniel Denvir

ACCC Conference

April 2011, Vol 2, No 2

Addressing the 2011 Association of Community Cancer Centers annual meeting attendees, Timothy Tyler, PharmD, FCSHP, Director of Pharmacy Services at the Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, CA, outlined the considerable demands and complications that have been added to oncology care with the introduction of the Risk Evaluation and Mitigation Strategies (REMS) program for high-risk drugs.

Oncologists Debate the Place of Pathways and Guidelines in Clinical Practice

By Daniel Denvir

ACCC Conference

April 2011, Vol 2, No 2

Implementing the HITECH Rules in Oncology Practices

By Gena Cook

ACCC Conference

April 2011, Vol 2, No 2